# A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

> **NCT00946699** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 50 (actual)

## Conditions studied

- Scleroderma

## Interventions

- **BIOLOGICAL:** MEDI-551
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** MEDI-551
- **BIOLOGICAL:** MEDI-551
- **BIOLOGICAL:** MEDI-551
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00946699
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-03
- **Final completion:** 2014-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946699, "A Study of the Safety and Tolerability of MEDI-551 in Scleroderma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00946699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*